久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

瑞典Cellartis AB
阿斯利康與瑞典Cellartis公司表示，二者已簽署了一項(xiàng)協(xié)議，延長(zhǎng)目前正在進(jìn)行的一項(xiàng)合作。該合作旨在開(kāi)發(fā)基于人類(lèi)胚胎干細(xì)胞生成的肝及心肌細(xì)胞的改良安全性篩選系統(tǒng)。

此次簽署的協(xié)議表明兩家公司將延長(zhǎng)于2006年7月簽署的一項(xiàng)為期兩年的合作協(xié)議，該協(xié)議旨在研究從已建立的人類(lèi)胚胎干細(xì)胞（hESC）生產(chǎn)線上獲得的細(xì)胞是否能夠被分化為機(jī)能人類(lèi)肝細(xì)胞及心肌細(xì)胞。兩家公司表示：“分化技術(shù)的進(jìn)一步改進(jìn)，將使科學(xué)家能夠在藥物開(kāi)發(fā)過(guò)程更早時(shí)期，更好地預(yù)測(cè)藥物的代謝以及其對(duì)人類(lèi)肝及心臟可能產(chǎn)生的副作用。”

Cellartis首席執(zhí)行官M(fèi)ats Lundwall表示，此項(xiàng)合作“目前正進(jìn)入令人興奮的階段”，其還表示：“我們一直在通過(guò)此類(lèi)交易確認(rèn)我們作為hESC領(lǐng)域領(lǐng)軍人物的聲譽(yù)。”

阿斯利康負(fù)責(zé)開(kāi)發(fā)事務(wù)的執(zhí)行副總裁Jan Lundberg表示：“如果我們能夠確實(shí)成功地建立一個(gè)分化胚胎干細(xì)胞的穩(wěn)定供應(yīng)，我們將能夠更準(zhǔn)確地檢測(cè)出新藥的副作用。”其還表示：“這一突破可能會(huì)降低損耗率從而提高研發(fā)生產(chǎn)力，并最終為患者提供更安全的藥物。盡管依然存在重大科學(xué)障礙，但我們正在取得良好的進(jìn)展并獲得寶貴的經(jīng)驗(yàn)。”（


Cellartis AB is a Swedish/British biotechnology company focused on human embryonic stem (hES) cells and technology for drug discovery research, toxicity testing and regenerative medicine. The company is the world’s largest single source of ethically derived hES cell lines and has developed more than 30 ethically derived cell lines. The main business objective of Cellartis is to develop hepatocytes and cardiomyocytes from the proprietary stem cells for use as tools in drug discovery.

The company's strategy is to accelerate product development by working in partnership with academia and industry towards advanced stem cell products and technologies. Cellartis was founded in 2001 and is located in state of art facilities in G?teborg, Sweden and in Dundee, UK. The laboratories are prepared to meet the EU guidelines for current Good Manufacturing Practice (cGMP).

Moreover, Cellartis has implemented a quality system and laboratory standards that meet the foreseeable future demands. Cellartis is focused on quality and scale-up production, which are crucial success factors for future growth. Therefore, Cellartis has expanded its operation into automated cell production and built the world's first production facility to make large volumes of hES cells.

Cellartis welcomes strategic alliances and are actively seeking collaboration partners from the pharmaceutical and biotechnology industries.